LIAISON 1-84 PTH Assay - Product Usage: is an in vitro chemiluminescent immunoassay (CLIA) intend...

FDA Device Recall #Z-1342-2021 — Class II — November 23, 2020

Recall Summary

Recall Number Z-1342-2021
Classification Class II — Moderate risk
Date Initiated November 23, 2020
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Diasorin Inc.
Location Stillwater, MN
Product Type Devices
Quantity 5,895 devices

Product Description

LIAISON 1-84 PTH Assay - Product Usage: is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of parathyroid hormone (1-84) in human serum and EDTA plasma. Measurements of parathyroid hormone levels are used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from disorders of calcium metabolism. The test has to be performed on the LIAISON¿ Analyzer family.

Reason for Recall

Potential for system to produce falsely elevated parathyroid hormone (PTH) results from patient samples.

Distribution Pattern

Worldwide distribution - US Nationwide in the states of KY, OH, GA, PA, FL and the countries of Canada, Argentina, Bahrain, Bosnia & Herzegovnia, Iraq, Jordan, Morocco, Nepal, Russia, Serbia, Singapore, Taiwan, Thailand, Tunisia, Dubai, Italy, Israel, Brazil, Mexico, Australia, and Bulgaria.

Lot / Code Information

REF 310630; lot numbers: 134909, 134909A and 134909B; UDI: 08056771600125

Other Recalls from Diasorin Inc.

Recall # Classification Product Date
Z-0677-2025 Class II DiaSorin LIAISON Q.S.E.T. Device Plus, REF 3190... Nov 7, 2024
Z-0815-2024 Class II DiaSorin LIAISON HSV-2 Type Specific IgG, REF 3... Dec 13, 2023
Z-2936-2020 Class II Parvovirus B19 IgG EIA kit Part No. V519IGUS Jul 17, 2020
Z-0645-2017 Class II LIAISON Estradiol II Gen, 310680, 310680-CN ... Jul 13, 2016
Z-1464-2015 Class II DiaSorin, PRO-Trac II Tacrolimus ELISA kit, REF... Mar 16, 2015

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.